Methadone as HIV prevention: High Volume Methadone Sites to decrease HIV incidence rates in resource limited settings

被引:57
作者
Bruce, R. Douglas [1 ]
机构
[1] Yale Univ, Sch Med, AIDS Programme, New Haven, CT 06510 USA
关键词
HIV prevention; Methadone; Opioid dependence; Injection drug use; INJECTION-DRUG USERS; ACTIVE ANTIRETROVIRAL THERAPY; FOLLOW-UP; MENTAL-ILLNESS; MAINTENANCE; IMPACT; BUPRENORPHINE; PREVALENCE; BEHAVIORS; INFECTION;
D O I
10.1016/j.drugpo.2009.10.004
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
The link between injection drug use and HIV has been extensively described. Despite worldwide prevention efforts, injection drug use continues to be a risk factor for HIV transmission and both HIV and injection drug use continues to spread across the globe. Although methadone has demonstrated multiple health benefits including the reduction in injection drug use and HIV acquisition, the utilisation of methadone in many areas of the world remains one of secondary, rather than primary, HIV prevention. As a result, many who finally begin methadone enter treatment having accumulated medical and mental health problems as a result of delayed treatment. Rapid access to treatment and a more aggressive policy that realizes that methadone can help reduce opioid drug use is necessary if methadone is effectively going to act as primary HIV prevention. To delay access to methadone only increases the probability that the individual will acquire an infectious disease that is more costly to the individual in terms of morbidity and mortality and more costly to society as a whole. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:122 / 124
页数:3
相关论文
共 32 条
[1]
Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia [J].
Abdala, N ;
Carney, JM ;
Durante, AJ ;
Klimov, N ;
Ostrovski, D ;
Somlai, AM ;
Kozlov, A ;
Heimer, R .
INTERNATIONAL JOURNAL OF STD & AIDS, 2003, 14 (10) :697-703
[2]
Ball J.C., 1991, EFFECTIVENESS METHAD
[3]
BATTJES RJ, 1991, J ACQ IMMUN DEF SYND, V4, P1148
[4]
Clinical care of the HIV-infected drug user [J].
Bruce, R. Douglas ;
Altice, Frederick L. .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2007, 21 (01) :149-+
[5]
Bruce RD., 2007, Infect Dis Clin North Am, V21, pix
[6]
BUNING EC, 1986, LANCET, V1, P1435
[7]
The dynamics of the human immunodeficiency virus epidemics in the south of Brazil: Increasing role of injection drug users [J].
Caiaffa, WT ;
Proietti, FA ;
Proietti, ABC ;
Mingoti, SA ;
Doneda, D ;
Gandolfi, D ;
Reis, ACM .
CLINICAL INFECTIOUS DISEASES, 2003, 37 :S376-S381
[8]
An 18-Year Follow-Up of Patients Admitted to Methadone Treatment for the First Time [J].
Davstad, Ingrid ;
Stenbacka, Marlene ;
Leifman, Anders ;
Romelsjo, Anders .
JOURNAL OF ADDICTIVE DISEASES, 2009, 28 (01) :39-52
[9]
Dolan K, 1996, BRIT MED J, V312, P1162, DOI 10.1136/bmj.312.7039.1162b
[10]
High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans [J].
Donny, EC ;
Walsh, SL ;
Bigelow, GE ;
Eissenberg, T ;
Stitzer, ML .
PSYCHOPHARMACOLOGY, 2002, 161 (02) :202-212